Evidence map›Paper›PMID 40329145›Full record

ArticleUpdates in surgery2025

Germline mutations of GCM2 cause a novel variant of hereditary primary hyperparathyroidism.

Maurizio Iacobone, Sara Watutantrige-Fernando, Stefania Zovato, Silvia Tognazzo, Silvia Dughiero, Veronica Augenti, Valentina Camozzi, Caterina Mian, Francesca Torresan, Claire Nomine-Criqui and 1 more

Abstract read
In one paragraph

Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maurizio IacoboneEndocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy. maurizio.iacobone@unipd.it.ORCID http://orcid.org/0000-0002-6057-4642
Sara Watutantrige-FernandoCancer Family Clinic, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.ORCID https://orcid.org/0000-0001-7056-0423
Stefania ZovatoCancer Family Clinic, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Silvia TognazzoCancer Family Clinic, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Silvia DughieroEndocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.
Veronica AugentiEndocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.
Valentina CamozziEndocrinology Unit, Department of Medicine, University of Padova, Padua, Italy.
Caterina MianEndocrinology Unit, Department of Medicine, University of Padova, Padua, Italy.
Francesca TorresanEndocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.
Claire Nomine-CriquiDepartment of Gastrointestinal, Visceral, Metabolic, and Cancer Surgery (CVMC), INSERM N-GERE, Université de Lorraine, CHRU Nancy, Nancy, France.
Laurent BrunaudDepartment of Gastrointestinal, Visceral, Metabolic, and Cancer Surgery (CVMC), INSERM N-GERE, Université de Lorraine, CHRU Nancy, Nancy, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary hyperparathyroidism (pHPT) occurs as hereditary disease in approximately 10% of cases. GCM2 germline mutations have been recently described as responsible for the development of a novel variant of hereditary pHPT. This study aimed to determine the features of GCM2-related pHPT. Demographics, laboratory, and surgical data were assessed in a series of 17 index cases carrying GCM2 mutations undergoing surgery for pHPT. The GCM2 germline pathogenic variant c.1181 A>C p.(Tyr394Ser) was detected in 59% of cases. GCM2-related pHPT was diagnosed at a median age of 57 years (range 32-82) with a Female/Male ratio 1.8. Preoperative median calcemia was 2.89 mmol/L (range 2.69-3.8). Family history of pHPT was absent in 65% of cases. Complete clinical, surgical and follow-up data were available for 13 patients. At initial surgery, bilateral neck exploration with subtotal parathyroidectomy was performed in 46% of patients; achieving cure in all cases at a median follow-up of 51 months (range 7-60). In the remaining cases undergoing selective parathyroidectomy, a persistent pHPT occurred in 3 cases; recurrent pHPT in 1 patient (after a disease-free interval of 4 years) while 3 are disease free at a mean follow-up of 21 months. Thus, at an overall prolonged follow-up (median 48 months, range 7-216), multiglandular involvement occurred in 77% of cases. GCM2 germline mutations may cause hereditary pHPT, even if it may mimic sporadic variant due to the absence of familial history and late onset. The main feature is multiglandular involvement, needing bilateral neck exploration and subtotal parathyroidectomy to achieve long-term cure.

Indexed as

Germ-Line MutationHyperparathyroidism, PrimaryNuclear ProteinsTranscription FactorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedParathyroidectomyGCM2 protein, humanNuclear ProteinsTranscription FactorsGCM2Hereditary hyperparathyroidismParathyroidectomyPrimary hyperparathyroidism

Identifiers

PMID40329145
PMCPMC12263790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.